pre-ipo
Stage
About
89bio is a clinical-stage biopharmaceutical company developing therapies based on FGF21 metabolic regulators to treat liver and cardiometabolic diseases with unmet medical needs.
Explore 89bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.